SCHEMBL189005

SCHEMBL189005

Nc1cccc(S(N)(=O)=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 13/20 1.00
CA1 P00915 10/20 1.00
CA9 Q16790 9/20 1.00
CA12 O43570 8/20 1.00
CA4 P22748 4/20 1.00
CA14 Q9ULX7 4/20 1.00
LMNA P02545 1/20 0.71
TSHR P16473 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
ALDH1A1 P00352 1/20 0.65
HSD17B10 Q99714 1/20 0.65
F2 P00734 1/20 0.55
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
CA5A P35218 3/20 0.54
CA6 P23280 2/20 0.54
CA7 P43166 2/20 0.54
CA13 Q8N1Q1 2/20 0.54
CA5B Q9Y2D0 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5633669 0.98 CA2 (0.95) CA2CA1CA9CA12CA4
SCHEMBL7117232 0.87 CA2 (0.77) CA2CA1CA9CA12CA4
SCHEMBL2398133 0.85 CA2 (1.00) CA2CA1CA9CA12CA4
SCHEMBL27698948 0.84 CA2 (0.70) CA2CA1CA9CA12CA4
SCHEMBL5561963 0.83 LMNA (1.00) CA2CA1CA9CA12CA4
SCHEMBL29635012 0.83 LMNA (1.00) CA2CA1CA9CA12CA4
SCHEMBL34546 0.83 LMNA (1.00) CA2CA1CA9CA12CA4
SCHEMBL30544199 0.83 LMNA (1.00) CA2CA1CA9CA12CA4
Alanine SCHEMBL28513478 0.82 CA1 (0.68) CA2CA1CA9CA12CA4
SCHEMBL4347220 0.81 CA1 (0.66) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745119-A1 ISOCYANATE COMPOSITION Hanwha Solutions Corporation (KR) 2026-05-20 EP claimed
WO-2025042219-A1 ISOCYANATE COMPOSITION 한화솔루션 주식회사 2025-02-27 WO claimed
CN-115430296-B Composite nanofiltration membrane with catalytic intermediate layer and preparation method and application thereof 中国科学院过程工程研究所 2025-02-21 CN claimed
CN-118807490-A Composite nanofiltration membrane based on oil immersed gel coating and preparation method thereof 中国科学院过程工程研究所 2024-10-22 CN claimed
CN-115869784-B Composite nanofiltration membrane based on primary layer solvent rearrangement and catalytic activation and preparation method and application thereof 中国科学院过程工程研究所 2024-09-24 CN claimed
CN-116272909-B Rotating wheel dehumidifier core material and preparation method thereof 集美大学 2024-07-05 CN claimed
CN-114614058-B Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2024-05-07 CN claimed
CN-117069627-A 4- (3- (3-sulfamoyl phenyl) ureido) butyric acid compound, fluorescent marker, preparation method and application thereof 上海康斯维克生物医药有限公司 2023-11-17 CN claimed
CN-116672886-A Acid-resistant nanofiltration membrane sheet and manufacturing method thereof 率氢技术(北京)股份有限公司 2023-09-01 CN claimed
CN-116396193-A Method for preparing alpha-sulfonamido acetals from fatty aldehydes and sulfonamides 西北工业大学 2023-07-07 CN claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2007041634-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2007-04-12 WO claimed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP claimed
WO-2007020046-A1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS NOVARTIS AG (CH) 2007-02-22 WO claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US claimed
US-20060111405-A1 O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives GU LIANQUAN 2006-05-25 US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO claimed
US-4083866-A Sulfonylamidino aminobenzaldehyde compounds CIBA-GEIGY CORPORATION (US) 1978-04-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG CA2 3151/4885CA1 2562/4885CA9 4341/4885
US-20060111405-A1 O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives PTGS2, PTGES2, PTGES CA2 1743/4885CA1 4180/4885CA9 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.